Neuro, Sorry for reposting your post. I was trying to save it as a word document, but being so dazed by the Stoll retirement news, I must have reposted it here by mistake.
I still can't believe there will be no more Stoll. I had to leave for work right after Varney's presentation, so I missed the 2nd half of the SHM..
The slides Varney had were excellent. Looks like CX-1763 is a prodrug, and can be used as an IV form. The pipeline is filling out nicely. Looks like everything is A-OK with CX-1837.
So the third dose cohort in RD-2 will be at 2100 mg. That's above the unofficial MTD of CX-717 (1600 mg), and I think it's the highest CX-717 has ever been dosed in humans. The trial design was for that cohort to be higher or lower than the 900 mg and 1500 mg cohorts, 'as needed'. So they obviously think they may need to go higher, which I guess isn't that surprising. Will have fingers crossed, but it's nice to be able to go that high with the dose. For some reason I don't understand, it looks like RD-2 isn't testing for maintenance of analgesia, only for prevention of RD. RD-1 on the other hand tests for both. Any ideas on why RD-2 wouldn't include the analgesia parameter? Thanks.
Market Data 
Markets 
AI
